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HEPATITIS B VACCINE IN INFANTS: A RANDOMIZED CONTROLLED TRIAL COMPARING GLUTEAL
VERSUS ANTEROLATERAL THIGH MUSCLE ADMINISTRATION
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SUMMARY
A significantly diminished antibody response to hepatitis B vaccine has been demonstrated in adults when the buttock is used as
the injection site. However, in Brazil,  the buttock continues to be recommended as site of injection for intramuscular administration
of vaccines in infants. In this age group, there are no controlled studies evaluating the immunogenicity of the hepatitis B vaccine when
administered at this site. In the present study, 258 infants were randomized to receive the hepatitis B vaccine either in the buttock (n
= 123) or in the anterolateral thigh muscle (n = 135). The immunization schedule consisted of three doses of hepatitis B vaccine
(Engerix B, 10 g) at 2, 4 and 9 months of age. There were no significant differences in the proportion of seroconversion (99.3% x
99.2%), or in the geometric mean titer of ELISA anti-HBs (1,862.1 x 1,229.0 mIU/mL) between the two groups. This study demonstrates
that a satisfactory serological response can be obtained when the hepatitis B vaccine is administered intramuscularly into the buttock.
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INTRODUCTION
Early studies on the response to hepatitis B vaccine have demonstrated
a 96% seroconversion rate in the target population28,29. However, in 1984
reports appeared of a serological efficacy of only 63 to 68% among
vaccinated health workers22,26. In 1985, a surveillance study by the Centers
for Disease Control and Prevention (CDC) in 57 hospitals in the United
States showed a significantly higher antibody response against the surface
antigen of the hepatitis B virus (anti-HBs) in hospitals where the deltoid
muscle was used as the injection site compared to the buttocks, 93% and
81% respectively3. Based on these findings, administration of hepatitis
B vaccine in the buttock is no longer recommended at any age.
Administration into the deltoid muscle is recommended for older children
and adults, while the anterolateral thigh muscle is preferred for infants
and toddlers. In 1998, the hepatitis B vaccine was introduced in the
National Immunization Program of the Ministry of Health of Brazil for
children under one year of age in all country and for children under 15
years of age in the States of Santa Catarina, Paraná, Distrito Federal and
in all the Amazonian region10. For infants the anterolateral thigh muscle
has been recommended as the injection site. However, in Brazil, the
application of intramuscular thigh injections still is not a well-established
routine since the buttock continues to be recommended as site of injection
for DPT vaccine11. The most recent data available from the Ministry of
Health of Brazil show that more than 14 million doses of DPT were
administered to children under 18 months of age in 199827. A concern
has been raised whether turning the anterolateral thigh muscle into the
mandatory injection site for hepatitis B administration could result in
additional difficulties in implementing children’s vaccination programs
due  to cultural and technical problems.
All studies reporting reduced  serological efficacy of hepatitis B vaccine
administered in the buttocks have been conducted on adults1,3,13,18,19,23,31,34.
In this age group, an inversely proportional correlation between a high
weight and height index and a satisfactory anti-HBs response has been
noted35. The present study was carried out to evaluate the serological
efficacy of hepatitis B vaccination in infants by comparing quantitative
anti-HBs levels as a consequence of the injection site used, taking into
consideration age, sex and nutritional status.
METHODS
Study design: A randomized controlled trial.
Calculation of sample size:  The sample size for the two groups
was calculated on the basis of a CDC study on adults3 that demonstrated
a serologic efficacy of 93.9% in vaccinated subjects who received the
hepatitis B vaccine in the deltoid, and an efficacy of 81.0% in subjects
receiving the vaccine in the buttock. Considering a 5% type I error and
90% statistical power, 157 children were recommended for each group.
Randomization: A total of 314 sealed envelopes containing 156
filling cards for group A (buttock) and 158 filling cards for group B
(anterolateral thigh muscle) were mixed by shuffling and then numbering
at random from 1 to 314. After the infants’ guardians gave written,
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informed consent, the envelopes were sequentially opened according to
admission to the study. Information was then obtained regarding the
group to which the infants had been assigned.
Study population:  The participants were selected from infants aged
two to four months whose parents spontaneously sought assistance at
one of the basic health units in the City of São Paulo where routine
medical visits are performed and the vaccines of the official immunization
program are provided. The study was conducted from January 1997 to
October 1998. The hepatitis B vaccine was not available to the public
health network when the study was performed. Infants whose parents
would not be available for follow-up or who did not agree with the
randomization of the injection site were not included in the study.
Children with a previous vaccination against hepatitis B, a history of
blood or immunoglobulin transfusion or of prolonged treatment with
corticosteroids, the presence of a clinical situation that would
contraindicate routine immunization, or the children of mothers known
or suspected to carry HIV or hepatitis B virus infection were also
excluded. The parents signed an informed consent form and the study
was approved by the Ethical Research Committee of the University of
São Paulo School of Medicine.
Intervention plan:  The Engerix B vaccine (Smith Kline Beecham,
Rixensart, Belgium) as a 10 g dose was injected IM into the upper,
outer right quadrant of the buttock (Group A) or into the anterolateral
surface of the right thigh (Group B). The nurses in charge of vaccine
administration were trained to apply IM injections into the anterolateral
thigh muscle. Needles measuring 30 or 25 mm in length by 0.7 mm in
diameter were used for the buttock  and  anterolateral thigh muscle
injections, respectively. The vaccine was stored at 2-8 oC.
Immunization schedule: The immunization schedule consisted of
three applications of hepatitis B vaccine (Engerix B, 10 g)  at 2, 4 and
9 months of age. As the hepatitis B vaccine was not provided by the
National Immunization Program when the study was carried out, this
immunization  schedule was established  to limit possible interference
with other routine vaccines. Concomitantly with the first and second
applications  of hepatitis B vaccine, the infants also received the oral
polio vaccine (OPV) and diphteria/tetanus/pertussis (DTP) vaccines, the
latter being injected into the upper, outer left quadrant of the buttock.
The measles vaccine was applied simultaneously with the third dose of
the hepatitis B vaccine. Different syringes, needles, and injection sites
were used for each vaccine. The vaccine against Haemophilus influenzae
type-b, also injected into the anterolateral thigh muscle, was  not available
to the public health network of the State of São Paulo during the study.
The collection of a post-vaccinal blood sample was scheduled for the
15th month of life. No blood samples were collected before vaccination
since infants previously vaccinated against hepatitis B virus were
excluded from the study. To detect infants eventually infected with the
wild virus, we tested the serum samples from non-responding infants
(anti-HBs levels < 10 mIU/mL) for the presence of the core antigen
antibody (anti-HBc) of the hepatitis B virus (Axsym – Abbott
Diagnostics, Abbott Park, IL, USA).
Detection of anti-HBs: An automated, quantitative
immunoenzymatic assay was performed to detect anti-HBs (Cobas Core
II, Roche Diagnostic Systems, Basel, Switzerland). The plasma
concentration of anti-HBs is given as mIU/mL. The anti-HBs response
was considered to be protective when it corresponded to  10 mIU/mL
and cases with antibody levels < 10 mIU/mL were considered to be non-
responders3. Samples with anti-HBs levels above 150 mIU/mL were first
diluted 1:10. Samples with titers higher than 1,500 mIU/mL were further
diluted to 1:100.
Anthropometric analysis: The nutritional status of the study
population was assessed by anthropometry. The calculations were based
on the standard growth curves elaborated by the U. S. National Center
for Health Statistics (NCHS) and by the CDC, using data from the Field
Research Institute and U. S. Health Examination Surveys recommended
by the World Health Organization37, with the aid of the Epi Info-6.0
nutritional anthropometry software. From the basic data on weight, sex,
age and height obtained during selection of the study population at the
time of the first application of hepatitis B vaccine, we calculated the two
major anthropometric indices, i.e., weight for height (WH) and height
for age (HA). These indices are reported in terms of Z-scores (WHZ and
HAZ)37. Thus, once the mean values for WHZ and HAZ were obtained,
it became possible to compare the two groups studied. The relationship
between nutritional status and antibody levels reached was also evaluated
(anti-HBs < 100 and anti-HBs > 100 mIU/mL).
Statistical analysis: First descriptive analysis (frequency
distribution, arithmetic and geometric means, medians and standard
deviation [SD] ) were calculated. The Student t-test was calculated to
compare means of normally distributed samples (age, weight and length);
when not applicable, Wilcoxon-Mann-Whitney U test was used25.
Quantitative variables were dichotomized into two categories, the cut-
off point lying close to the median. The efficacy of the vaccine in each
group was assessed from the proportion of non-responders according to
the injection site studied. To analyze the variable anti-HBs > 10 mIU/
mL according to the group studied, we also calculated the geometric
mean for antibody levels, which is not affected by extreme values. The
group of infants with anti-HBs levels < 100 mIU/mL was analyzed
separately by univariate analysis to detect typical characteristics, and
later by unconditional logistic regression to control for possible
confounding variables17. The strength of the association between variables
was estimated by calculating the odds ratio (OR) and 95% confidence
interval (95% CI). Statistical significance was evaluated by the likelihood
ratio test (LR).
RESULTS
Of 314 infants, 258 (82.2%) completed all stages of the study. No
significant differences were observed between the group that concluded
the study and the infants lost to follow-up with respect to age, sex, weight,
height, and vaccine application site. Of those who remained in the study
(n = 258), the mean interval (SD) between the 1st and the 2nd vaccine
applications was 67.0 days (15.8 days), that between the 2nd and 3rd doses
was 175.8 days (40.7 days), and that between the 3rd dose and blood
collection was 144.5 days (50.5 days). No significant differences were
seen in the characteristics of the infants who received the vaccine in the
anterolateral thigh muscle or in the buttock (Table 1).
Only 2 of the 258 infants presented  non-protective (< 10 mIU/mL)
post-vaccinal antibody levels. Each non-responder case belonged to one
of the two groups, resulting in a serological efficacy of 99.3% (134/135)
for the anterolateral thigh muscle group and an efficacy of 99.2% (122/
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123) for the buttock group. No anti-HBc  was found in these cases. The
geometric mean titer of anti-HBs was 1,229.0 mIU/mL for the buttock
group and 1,862.1 mIU/mL for the anterolateral thigh muscle group (p
= 0.06). The median anti-HBs titer was 2,051 mIU/mL for the
anterolateral thigh muscle group and 1,485 mIU/mL for the buttock group
(p = 0.14).
Twenty-two of the 258 infants (8.5%) had anti-HBs levels < 100
mIU/mL. Of these, seven belonged to the 135 infants who received the
vaccine in the anterolateral thigh muscle (5.2%) and 15 belonged to the
group of 123 infants who received the vaccine in the buttock (12.2%).
This difference was statistically significant (OR = 2.54, p = 0.04).
Univariate analysis of the main characteristics of the infants with anti-
HBs levels < 100 mIU/mL (injection site, nutritional status, interval
between vaccine applications and interval between the 3rd vaccine dose
and blood collection) showed that the single factor related to this type of
response was the vaccination site (p = 0.04). Multivariate analysis for
the control of possible confounding variables (age, sex, weight, length,
interval between vaccine applications, and interval between the 3rd vaccine
dose and blood collection) showed that injection into the buttock
continued to be a significant independent factor associated with anti-
HBs levels < 100 mIU/mL (OR = 2.60, p = 0.04). Eighty-one of the
infants studied exhibited anti-HBs levels > 5,000 mIU/mL after
vaccination, 36  belonging to the buttock group and 45 to the anterolateral
thigh muscle group (p = 0.08).
DISCUSSION
The hepatitis B vaccine administered IM to infants was highly
effective regardless of the application site. Only two infants did not exhibit
seroconversion at the end of the study, each belonging to a different
group. No difference in the geometric mean of anti-HBs levels > 10
mIU/mL was detected between the groups vaccinated in the anterolateral
thigh muscle or in the buttock.
These results agree with previous reports on the high immunogenicity
of hepatitis B vaccine in children15,16,36, but differ from reports of vaccine
failure after administration in the buttocks of adults1,3,13,18,19,23,31,34. A
previous study, analyzing the risk factors associated with a diminished
response to hepatitis B vaccine among health professionals vaccinated
in the buttocks, demonstrated that obese individuals presented an
unsatisfactory immunological response35. A study using pelvic
computerized tomography demonstrated that most of the IM injections
in the buttocks of adults actually resulted in the inadvertent application
into adipose tissue in 85.0% of males and at least 95.0% of females6.
These results were extrapolated to infants and children, and
recommendations were made not to inject hepatitis B vaccine into the
buttocks of adults or children3.
In the present study, the WH and HA indices, expressed as Z-scores37,
were similar in the two groups studied, even for infants presenting anti-
HBs levels < 100 mIU/mL. Comparison of the risk of vaccine failure
(anti-HBs < 10 mIU/mL) with respect to the nutritional profile of each
study group was not performed due to the small number of infants
presenting this response (one child in each group).
The fact that the two groups showed a  similar proportion of
seroconversion may be of practical importance since not all public health
units in developing countries are staffed by workers trained in
administering IM injections into the anterolateral thigh muscle. If the
buttock is considered a possible alternative for hepatitis B vaccine
administration, many operational and cultural problems may be avoided,
eliminating possible delays in the implementation of infant immunization
against hepatitis B.
No significant difference in anti-HBs levels > 5,000 mIU/ml was
detected between groups. However, when the number of infants with
anti-HBs levels < 100 mIU/mL was analyzed, a significant association
was obtained between this parameter and the vaccine administration site
(p = 0.04). In the multivariate analysis, the only variable associated with
anti-HBs levels < 100 mIU/mL was the vaccine application site (OR =
2.54, 95% CI = 1.02-6.76). However, the prevalence of infants with
post-vaccination levels < 100 mIU/mL was low, both in the study
population as a whole (8.5%) and in each group specifically (5.2 % for
the group vaccinated in the anterolateral  thigh muscle and 12.2% for
the group vaccinated in the buttock).
The clinical significance of this  response pattern to hepatitis B
vaccine is not well defined. Some investigators believe that anti-HBs
levels after vaccination should exceed 100 mIU/mL since there are reports
of individuals with anti-HBs levels < 100mIU/mL who present clinical
or subclinical hepatitis B virus infection with transiently positive
antigenemia and hepatitis B virus DNA2,5. Other investigators prefer the
use of terms such as “seroconverted” for subjects who exhibit an anti-
HBs response > 10 mIU/mL, as opposed to the term “seroprotected”,
which is reserved for those whose anti-HBs levels exceed 100 mIU/
mL4,5,14.
Studies involving the clinical and laboratory monitoring of
populations at a high risk of acquiring the hepatitis B virus have
demonstrated that the hepatitis B vaccine induces a long-lasting protective
immune response. Natural boosters occur frequently and, due to an
anamnestic type response, even individuals considered to be low
Table 1
Characteristics of the infants receiving hepatitis B vaccine in the anterolateral
thigh muscle or  in the buttock* and intervals (days) between 1st , 2nd  and 3rd
application of vaccine and between 3rd vaccine application and blood post-
vaccinal collection (mean ±SD)




Sex (female) 63 (46.7%) 63 (51.2%)
Age (days) 74.1 ± 15.2 73.6 ± 14.9
Weight (Kg) 5.5 ± 0.8 5.5 ± 0.9
Length (cm) 56.7 ± 3.1 56.8 ± 3.2
Dose interval (1st and 2nd) 67.9 ± 17.1 66.4 ± 14.1
Dose interval (2nd and 3rd) 173.4 ± 36.0 178.5 ± 45.3
Interval between 3rd  dose 144.6 ± 51.1 144.4 ± 50.2
and blood collection
* The differences are not statistically significant
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responders (anti-HBs < 100 mIU/mL) continue to be protected against
chronic hepatitis B virus infection for years8,21,24, 32.
Additional booster doses of hepatitis B vaccine are not recommended
by the World Health Organization. Recent studies have shown that
vaccine-dependent immunity is of long duration, suggesting that there
is no need to administer booster doses of the vaccine to prevent a fall in
or  disappearance of anti-HBs levels over the years21,33.
The administration of IM injections into the buttock is believed to
involve greater risk than that into the anterolateral thigh muscle because
of possible damage to the sciatic nerve. However, in most reported cases
of sciatic nerve palsies in infants and children after gluteal injections there
was evidence of direct injection of neurotoxic material, such as antibiotics,
bismuth and quinine, into or near the nerve7,12. Otherwise, there are also
anecdotal reports of complications following intramuscular injections into
the anterolateral thigh muscle, including  muscle necrosis deep to the fascia
lata, acute chemical synovitis, and fibrosis and contracture of the quadriceps
muscle resulting in loss of knee flexion9,20,30. There are no controlled,
prospective studies comparing the risks involved in the use of these two
injection sites for immunization in infants. In Brazil, approximately 15
million doses of vaccines are administered each year to infants using the
buttock as site of injection. In the present study a satisfactory  serological
response was observed in infants when the hepatitis B vaccine was
administered into the buttock suggesting that this procedure may be
considered in environments where, for cultural or operational reasons, it
can facilitate the implementation of  vaccination programs.
RESUMO
Vacina da hepatite B em lactentes: um ensaio clínico controlado,
aleatorizado, comparando a administração no glúteo com a
administração no vasto lateral da coxa
Diminuição significativa da resposta sorológica à vacina da hepatite
B foi documentada em adultos quando a mesma é aplicada no glúteo.
Entretanto, em alguns países, o glúteo ainda é bastante utilizado para
aplicação intramuscular de vacinas em lactentes. Nesta faixa etária, não
há estudos controlados que tenham avaliado a imunogenicidade da vacina
da hepatite B quando administrada em diferentes locais.  No presente
estudo, 258 lactentes foram sorteados de forma aleatória para receber a
vacina da hepatite B no glúteo (n = 123) ou no músculo vasto lateral da
coxa (n = 135). O esquema vacinal consistiu em 3 doses da vacina da
hepatite B (Engerix B, 10 g) aos 2, 4 e 9 meses de idade. Não se
observaram diferenças significativas nas proporções de soroconversão
(99,3% X 99,2%), ou na média geométrica dos títulos de anti-HBs (1.862
X 1.229 mUI/mL) entre os dois grupos. Este estudo demonstra uma
resposta sorológica satisfatória em lactentes quando a  vacina da hepatite
B é aplicada no glúteo.
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